Talaris Therapeutics is developing an innovative and proprietary method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care across numerous therapeutic areas. With Facilitated Allo-HSCT Therapy, we aim to remove solid organ transplantation recipients’ need for chronic immunosuppression and treat patients who suffer from severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders.
“Talaris Therapeutics is developing an innovative and proprietary method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care across numerous therapeutic areas. With Facilitated Allo-HSCT Therapy, we aim to remove solid organ transplantation recipients’ need for chronic immunosuppression and treat patients who suffer from severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders.”